🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Susumu Kobayashi

Beth Israel Deaconess Medical Center

ORCID: 0000-0003-2262-4001

Also affiliated with Harvard University

MedicineChemistryBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 4%percentile
0.757Author DataRank

Indexed papers

1in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Top data-sharing exemplar

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

A Real-World Study of Patient Characteristics and Clinical Outcomes in EGFR Mutated Lung Cancer Treated with First-Line Osimertinib: Expanding the FLAURA Trial Results into Routine Clinical Practice

Cancers(2024)10.3390/cancers16061079
Top 27%
0.757DataRank
Top 27%17 citations

Andrew J. Piper‐Vallillo, Page Widick, Emmeline C. Academia, Meghan Shea, Deepa Rangachari +4 more

Papers

Driven by 28 papers — median percentile 73. Top paper: “A Real-World Study of Patient Characteristics and Clinical Outcomes in EGFR Mutated Lung Cancer Treated with First-Line Osimertinib: Expanding the FLAURA Trial Results into Routine Clinical Practice”.

A Real-World Study of Patient Characteristics and Clinical Outcomes in EGFR Mutated Lung Cancer Treated with First-Line Osimertinib: Expanding the FLAURA Trial Results into Routine Clinical Practice

Cancers(2024)10.3390/cancers16061079
Top 27%
0.757DataRank
Top 27%17 citations

Andrew J. Piper‐Vallillo, Page Widick, Emmeline C. Academia, Meghan Shea, Deepa Rangachari +4 more

CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistance

Cancer Cell(2023)10.1016/j.ccell.2023.01.007
N/A
0.700DataRank · unranked
105 citations

Yan Yang, Simon Heeke, Sonia Patel, Alissa Poteete, Hibiki Udagawa +22 more

The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies

UNC Libraries(2021)10.17615/6prg-vp52
N/A
0.546DataRank · unranked
37 citations

Hongbin Ji, Norman E. Sharpless, Pasi A. Jänne, Mitchell Albert, Daniel G. Tenen +16 more

NAD Modulates DNA Methylation and Cell Differentiation

Cells(2021)10.3390/cells10112986
N/A
0.494DataRank · unranked
26 citations

Clinton Hausman, Giulia Gaggi, Lucrezia Rinaldi, Mahmoud A. Bassal, Yanzhou Zhang +9 more

Acquired Resistance to Osimertinib Plus Savolitinib Is Mediated by MET-D1228 and MET-Y1230 Mutations in EGFR-Mutated MET-Amplified Lung Cancer

JTO Clinical and Research Reports(2020)10.1016/j.jtocrr.2020.100071
N/A
0.470DataRank · unranked
22 citations

Brian Halbert, Deepa Rangachari, Susumu Kobayashi, Daniel B. Costa, Andrew J. Piper‐Vallillo

Preclinical characterization of mobocertinib highlights the putative therapeutic window of this novel EGFR inhibitor to EGFR exon 20 insertion mutations

bioRxiv (Cold Spring Harbor Laboratory)(2020)10.1101/2020.09.28.317560
N/A
0.457DataRank · unranked
20 citations

Ikei S. Kobayashi, Susumu Kobayashi, Daniel B. Costa, Pedro Eduardo Nascimento Silva Vasconcelos

TIP60 is required for tumorigenesis in non‐small cell lung cancer

Cancer Science(2023)10.1111/cas.15785
N/A
0.449DataRank · unranked
19 citations

Naoki Akanuma, Ikei S. Kobayashi, Eunyoung Heo, Mariko Ando, Masanori Fujii +10 more

EGFR exon 19 insertion EGFR-K745_E746insIPVAIK and others with rare XPVAIK amino-acid insertions: Preclinical and clinical characterization of the favorable therapeutic window to all classes of approved EGFR kinase inhibitors

Lung Cancer(2023)10.1016/j.lungcan.2023.107250
N/A
0.292DataRank · unranked
6 citations

Ikei S. Kobayashi, Daniel Sentana‐Lledo, Shriram K. Sundararaman, Meghan Lee, Deepa Rangachari +4 more

EGFR exon 20 insertion mutations and ERBB2 mutations in lung cancer: a narrative review on approved targeted therapies from oral kinase inhibitors to antibody-drug conjugates

Translational Lung Cancer Research(2023)10.21037/tlcr-23-98
N/A
0DataRank · unranked
33 citations

Emmeline C. Academia, Hollis Viray, Deepa Rangachari, Susumu Kobayashi, Paul A. VanderLaan +2 more

The Impact of On-Target Resistance Mediated by EGFR-T790M or EGFR-C797S on EGFR Exon 20 Insertion Mutation Active Tyrosine Kinase Inhibitors

JTO Clinical and Research Reports(2023)10.1016/j.jtocrr.2023.100614
N/A
0DataRank · unranked
11 citations

William O. Shaffer, Hollis Viray, Deepa Rangachari, Paul A. VanderLaan, Susumu Kobayashi +2 more

Data from Resistance to an Irreversible Epidermal Growth Factor Receptor (EGFR) Inhibitor in EGFR-Mutant Lung Cancer Reveals Novel Treatment Strategies

(2023)10.1158/0008-5472.c.6496299
N/A
0DataRank · unranked
0 citations

Titus J. Boggon, Susumu Kobayashi, Cheng Jin, C. Patrick, Afshin Dowlati +4 more

Data from Transcriptional Profiling Identifies Cyclin D1 as a Critical Downstream Effector of Mutant Epidermal Growth Factor Receptor Signaling

(2023)10.1158/0008-5472.c.6495248
N/A
0DataRank · unranked
0 citations

Takeshi Shimamura, Stefano Monti, Ulrich Steidl, Christopher J. Hetherington, April M. Lowell +6 more

Data from Transcriptional Profiling Identifies Cyclin D1 as a Critical Downstream Effector of Mutant Epidermal Growth Factor Receptor Signaling

(2023)10.1158/0008-5472.c.6495248.v1
N/A
0DataRank · unranked
0 citations

Takeshi Shimamura, Stefano Monti, Ulrich Steidl, Christopher J. Hetherington, April M. Lowell +6 more

Data from Resistance to an Irreversible Epidermal Growth Factor Receptor (EGFR) Inhibitor in EGFR-Mutant Lung Cancer Reveals Novel Treatment Strategies

(2023)10.1158/0008-5472.c.6496299.v1
N/A
0DataRank · unranked
0 citations

Titus J. Boggon, Susumu Kobayashi, Cheng Jin, C. Patrick, Afshin Dowlati +4 more

Data from Upregulation of FGF9 in Lung Adenocarcinoma Transdifferentiation to Small Cell Lung Cancer

(2023)10.1158/0008-5472.c.6513297.v1
N/A
0DataRank · unranked
0 citations

Hiroyuki Yasuda, Junko Hamamoto, Hideki Terai, Katsura Emoto, Tae Jung Kim +30 more

Data from Single-Cell Analyses Reveal Diverse Mechanisms of Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Cancer

(2023)10.1158/0008-5472.c.6512902.v1
N/A
0DataRank · unranked
0 citations

Daisuke Shibahara, Ayako Suzuki, Kyoko Muto, Ikei S. Kobayashi, David Plotnick +12 more

Integrative single-cell RNA-seq and spatial transcriptomics analyses reveal diverse apoptosis-related gene expression profiles in EGFR-mutated lung cancer

Cell Death and Disease(2024)10.1038/s41419-024-06940-y
N/A
0DataRank · unranked
18 citations

Masanori Fujii, Ikei S. Kobayashi, Vivian Ho, Yukie Kashima, Hibiki Udagawa +3 more

Targeting of drug-tolerant persister cells as an approach to counter drug resistance in non-small cell lung cancer

Lung Cancer(2024)10.1016/j.lungcan.2024.107885
N/A
0DataRank · unranked
15 citations

Daniel B. Costa, Susumu Kobayashi, Motohiro Izumi

Small activating RNA AW1-51 (CEBPA-51) elicits targeted DNA demethylation to promote gene activation

bioRxiv (Cold Spring Harbor Laboratory)(2025)10.1101/2025.09.29.679274
N/A
0DataRank · unranked
1 citations

Juan Rodrigo Patiño-Mercau, Marta Borchiellini, Mailin Li, Lucrezia Rinaldi, Giorgia Maroni +12 more

EGFR-A763_Y764insFQEA Is a Unique Exon 20 Insertion Mutation That Displays Sensitivity to Approved and In-Development Lung Cancer EGFR Tyrosine Kinase Inhibitors

JTO Clinical and Research Reports(2020)10.1016/j.jtocrr.2020.100051
N/A
0DataRank · unranked
81 citations

Carol Gergis, Hollis Viray, Andreas Varkaris, Masanori Fujii, Deepa Rangachari +5 more

Efficacy of EGFR tyrosine kinase inhibitors in patients with non–small cell lung cancer with EGFR exon 19 insertions: clinical-genomic, preclinical analysis through LC-SCRUM-Asia (multi-institutional genomic screening registry)

Lung Cancer(2025)10.1016/j.lungcan.2025.108479
N/A
0DataRank · unranked
0 citations

Hiroki Izumi, Ikei S. Kobayashi, Shingo Matsumoto, Yukio Hosomi, Takae Okuno +23 more

Preclinical Characterization of Mobocertinib Highlights the Putative Therapeutic Window of This Novel EGFR Inhibitor to EGFR Exon 20 Insertion Mutations

JTO Clinical and Research Reports(2020)10.1016/j.jtocrr.2020.100105
N/A
0DataRank · unranked
23 citations

Ikei S. Kobayashi, Susumu Kobayashi, Daniel B. Costa, Pedro Eduardo Nascimento Silva Vasconcelos

Alternative splicing of APOBEC3D generates functional diversity and its role as a DNA mutator

International Journal of Hematology(2020)10.1007/s12185-020-02904-y
N/A
0DataRank · unranked
7 citations

Hirofumi Fukuda, Gilbert Pan, Hiroyuki Yamazaki, Tadahiko Matsumoto, Yasuhiro Kazuma +9 more

Long-read sequencing for non-small-cell lung cancer genomes

Genome Research(2020)10.1101/gr.261941.120
N/A
0DataRank · unranked
51 citations

Liu Xu, Masahide Seki, Toshiyuki Yokoyama, Masahiro Kasahara, Yukie Kashima +10 more

Single-Cell Analyses Reveal Diverse Mechanisms of Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Cancer

Cancer Research(2021)10.1158/0008-5472.can-20-2811
N/A
0DataRank · unranked
104 citations

Daisuke Shibahara, Ayako Suzuki, Kyoko Muto, Ikei S. Kobayashi, David Plotnick +12 more

Myeloid lncRNA LOUP mediates opposing regulatory effects of RUNX1 and RUNX1-ETO in t(8;21) AML

Blood(2021)10.1182/blood.2020007920
N/A
0DataRank · unranked
38 citations

Simone Ummarino, Yanzhou Zhang, Alexander K. Ebralidze, Mahmoud A. Bassal, Tuan M. Nguyen +23 more

Suppression of multiple anti‐apoptotic BCL2 family proteins recapitulates the effects of JAK2 inhibitors in JAK2V617F driven myeloproliferative neoplasms

Cancer Science(2021)10.1111/cas.15210
N/A
0DataRank · unranked
6 citations

Juan Luiz Coelho‐Silva, Cristina Tavares Leal, Adriana Queiroz Arantes Rocha, Thiago Mantello Bianco, Robert S. Welner +8 more

Differential Pattern of Resistance and Sensitivity to Different Classes of MET Inhibitors for MET-Amplified Tumors With MET-D1228X or MET-Y1230X Mutations

JTO Clinical and Research Reports(2021)10.1016/j.jtocrr.2020.100133
N/A
0DataRank · unranked
0 citations

Susumu Kobayashi, Daniel B. Costa, Andrew J. Piper‐Vallillo